Malekzadeh et al. developed a high-throughput screening method involving mutation-containing tandem minigenes, TILs, and autologous APCs to identify T cells recognizing mutations in the 8 most commonly mutated TP53 positions. In 28 patients with PBL and TIL samples, 11 were found to have CD4+ and/or CD8+ TILs reactive against TP53 neoantigens in an HLA-restricted manner. Some T cells recognized endogenously-presented mutated p53 neoepitopes and showed upregulation of degranulation and cytolysis markers. The researchers generated a library of 9 p53 neoantigen-specific TCRs, indicating potential for off-the-shelf targeted immunotherapy.
Author Info: (1) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (2) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (3) Surgery Branch, National Cancer
Author Info: (1) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (2) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (3) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (4) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (5) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (6) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (7) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (8) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (9) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (10) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (11) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (12) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA. (13) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (14) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (15) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. (16) Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA.
